METHOD FOR DETERMINING THE RISK OF PREECLAMPSIA USING PIGF-2 AND PIGF-3 MARKERS

• US 20110294227A1
• Filed: 11/20/2009
• Published: 12/01/2011
• Est. Priority Date: 11/20/2008
• Status: Abandoned Application

• Current Assignee: NTD Laboratories Incorporated (Eurofins Scientific SE), Wallac Oy (Revvity, Inc.)
• Original Assignee: NTD Laboratories Incorporated (Eurofins Scientific SE), Perkinelmer Health Sciences Incorporated (Perkinelmer Incorporated), Wallac Oy (Revvity, Inc.)
• Inventors: Ahola, Tarja, Carmichael, Jonathan B., Korpimäki, Teemu, Bobrow, Mark N., Frang, Heini, Hurskainen, Pertti
• Application Number:
  US13/130,086
• Publication Number:
  US 20110294227A1
• Time in Patent Office: Days
• US Class Current: 436/501
• CPC Class Codes: G01N 2800/368 Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
• CPC Class Codes: G01N 33/689 related to pregnancy or the gonads
• CPC Class Codes: G16B 50/00 ICT programming tools or database systems specially adapted for bioinformatics

Abstract

The present invention relates to a method for determining the risk of a pregnant woman developing pre-eclampsia. The method comprises i) determining the level of one or more biochemical markers in a sample obtained from a pregnant woman, and ii) comparing the level of the at least one biochemical marker in the sample with the level of the same biochemical marker in a control sample. A difference in the level of the biochemical marker in the sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia. The isoform biochemical markers are preferably P1GF-2 and P1GF-3. The present invention relates also to a method for determining whether a pregnant woman has pre-eclampsia and as well as a kit for assessing the risk or presence of pre-eclampsia. In addition, the invention relates also to a computer program used in these determinations.

Claims

1. A method for determining the risk of a pregnant woman developing pre-eclampsia, comprising:

i) determining selectively the level of one or more biochemical markers in a sample obtained from a pregnant woman, wherein at least one biochemical marker is a P1GF isoform selected from P1GF-2 and P1GF-3;

ii) comparing the level of the at least one biochemical marker in the sample with the level of the same biochemical marker in a control sample;

wherein a difference in the level of the at least one biochemical marker in the sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia.

2. The method according to claim 1, wherein the level of PIGF-2 is determined, and wherein an increased level of P1GF-2 in the sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia.

3. The method according to claim 2, wherein the level of P1GF-3 is determined, and wherein a decreased level of P1GF-3 in the subject sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia.

4. The method according to claim 1, wherein a difference in the ratio of PIGF-2/PIGF-3 is determined, and wherein a difference in ratio in the subject sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia.

5. The method according to claim 1, wherein the level of PIGF-3 is determined, and wherein a decreased level of P1GF-3 in the subject sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia.

6. The method according to claim 5, wherein the level of P1GF-2 is determined, and wherein an increased level of P1GF-2 in the subject sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia.

7. The method according to any one of claims 1 to 6, wherein at least one biochemical marker is selected from PAPP-A, PAI-1, PAI-2, P1GF-1 and ADAM-12.

8. The method according to claim 7, wherein the level of P1GF-1 is determined, and wherein a decreased level of P1GF-1 in the subject sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia.

9. The method according to claim 1, wherein the ratio of PIGF-2/PIGF-1 is determined, and wherein a difference in the ratio in the subject sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia.

10. The method according to claim 1, wherein a sample is obtained from a subject during the first trimester of pregnancy.

11. The method according to claim 1, wherein a sample is obtained from a subject during the second trimester of pregnancy.

12. The method according to claim 1, further comprising determining one or more biophysical markers of the pregnant woman, comparing each of the one or more biophysical markers with the same biophysical marker in a control subject, wherein an increased or decreased measure of each biophysical marker in the pregnant woman relative to the control is indicative of an increased risk of developing pre-eclampsia.

13. The method of claim 12, wherein the biophysical marker is selected from blood pressure and uterine artery pulsatility index.

14. A method for determining whether a pregnant woman has pre-eclampsia, comprising:

i) determining selectively the level of one or more biochemical markers in a sample obtained from a pregnant woman, wherein at least one biochemical marker is a P1GF isoform selected from P1GF-2 and P1GF-3;

ii) comparing the level of the at least one biochemical marker in the sample with the level of the same biochemical marker in a control sample;

wherein a difference in the level of the at least one biochemical marker in the subject sample relative to the control sample is indicative of pre-eclampsia.

15. The method according to claim 14, wherein at least one of the following observations are made:

the level of PIGF-2 in a sample obtained from a subject is increased relative to the level of PIGF-2 in the control sample; and

the level of PIGF-3 in a sample obtained from a subject is decreased relative to the level of PIGF-3 in the control sample.

16. The method according to claim 14 or 15, wherein a difference in ratio of PIGF-2/PIGF-1 in a sample obtained from a subject relative to the control sample is indicative of an increased risk of developing pre-eclampsia.

17. The method according to claim 14 or 15, wherein a difference in the ratio of PIGF-2/PIGF-3 in a sample obtained from a subject relative to the control sample is indicative of an increased risk of developing pre-eclampsia.

18. The method according to claim 14, wherein a sample is obtained from the pregnant woman during weeks 20-40 of pregnancy.

19. A computer program which when executed on a computer causes the computer to perform a process for determining risk or presence of pre-eclampsia in a pregnant woman, the process comprising:

inputting a measurement of at least one biomarker obtained by;

1) assaying a sample obtained from the pregnant woman for one or more biochemical markers, wherein at least one biochemical marker is selected from PIGF-2 and PIGF-3;

ii) comparing the level of the one or more biochemical marker in the sample with the level of the same biochemical marker in a control sample, wherein a difference in level of the one or more biochemical marker in the sample relative to the control sample is indicative of pre-eclampsia, and

iii) determining a quantitative estimate of pre-eclampsia risk based on the result of the comparing.

20. The computer program according to claim 19, further comprising assaying for at least one biochemical marker selected from the group comprising PAPP-A, PAI-1, PAI-2, P1GF-1 and ADAM-12.

21. The computer program according to claim 19 or 20, further comprising inputting a measurement of at least one biomarker obtained by determining one or more biophysical markers of the subject;

comparing the one or more biophysical markers of the subject with the same biophysical marker in a control subject, wherein an increased or decreased measure of the one or more biophysical marker in the subject relative to the control is indicative of an increased risk of developing pre-eclampsia, and determining a quantitative estimate of pre-eclampsia risk based on the result of the compared one of more biochemical marker and the compared one or more biophysical marker.

22. The computer program according to claim 21, wherein the biophysical marker is selected from blood pressure and uterine artery pulsatility index.

23. The computer program according to claim 19, wherein determining the quantitative estimate of pre-eclampsia risk comprises determining the likelihood of pre-eclampsia using a multivariate analysis, and wherein the multivariate analysis comprises using levels of the biochemical markers and distribution parameters derived from a set of control reference data.

24. A computer program according to claim 22, wherein said multivariate analysis is a multivariate Gaussian analysis.

25. A computer program recording medium storing a computer program according to claim 19.

26. A kit for assessing risk or presence of pre-eclampsia in a pregnant woman, comprising:

i) at least two detectable binding partners, wherein each detectable binding partner binds specifically to an individual P1GF isoform selected from PIGF-1, PIGF-2 and PIGF-3.

27. The kit according to claim 26, comprising:

i) a detectable binding partner that binds specifically to PIGF-2, and

ii) a detectable binding partner that binds specifically to a P1GF isoform selected from P1GF-1 and PIGF-3.

28. The kit according to claim 26, comprising:

i) a detectable binding partner that binds specifically to PIGF-3, and

ii) a detectable binding partner that binds specifically to a P1GF isoform selected from P1GF-1 and PIGF-2.

29. The kit according to any one of claims 26 to 28, wherein the detectable binding partner is an antibody or antigen-binding fragment thereof.

31. The kit according to claim 26 or 30, wherein the antibody or antigen-binding fragment thereof binds to the loop 3 structure of the P1GF isoform.

30. A kit for assessing risk and presence of pre-eclampsia in a pregnant woman, comprising:

i) at least one antibody or an antigen-binding fragment thereof, that binds specifically to a P1GF isoform selected from PIGF-2 and PIGF-3;

ii) instructions for using the antibody or antigen-binding fragment in the determination.

32. The kit according to claim 30, wherein the antibody or antigen-binding fragment thereof binds to the sequence between amino acids 124 to 144 in mature PIGF-2 (SEQ ID NO:

6) and/or to the sequence between amino acids 114 to 185 in mature PIGF-3 (SEQ ID NO;

7).

33. The kit according to claim 32, wherein the antibody or antigen-binding fragment thereof binds to a P1GF-3 sequence selected from HSPGRQSPDMPGDFRADA (SEQ ID NO:

8) and PEEIPRMHPGRNGKKQQRK (SEQ ID NO;

9).